Literature DB >> 33139380

Chlamydia-Specific IgA Secretion in the Female Reproductive Tract Induced via Per-Oral Immunization Confers Protection against Primary Chlamydia Challenge.

Nita Shillova1, Savannah E Howe1,2, Besmir Hyseni1, Deahneece Ridgell1, Derek J Fisher1, Vjollca Konjufca3.   

Abstract

Chlamydia trachomatis is an obligate intracellular pathogen that causes sexually transmitted disease. In women, chlamydial infections may cause pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. The role of antibodies in protection against a primary Chlamydia infection is unclear and was a focus of this work. Using the C. muridarum mouse infection model, we show that intestinal mucosa is infected via intranasal (i.n.) or per-oral (p.o.) Chlamydia inoculation and that unlike the female reproductive tract (FRT) mucosa, it halts systemic Chlamydia dissemination. Moreover, p.o. immunization or infection with Chlamydia confers protection against per-vaginal (p.v.) challenge, resulting in significantly decreased bacterial burden in the FRT, accelerated Chlamydia clearance, and reduced hydrosalpinx pathology. In contrast, subcutaneous (s.c.) immunization conferred no protection against the p.v. challenge. Both p.o. and s.c. immunizations induced Chlamydia-specific serum IgA. However, IgA was found only in the vaginal washes and fecal extracts of p.o.-immunized animals. Following a p.v. challenge, unimmunized control and s.c.-s.c.-immunized animals developed Chlamydia-specific intestinal IgA yet failed to develop IgA in the FRT, indicating that IgA response in the FRT relies on the FRT to gastrointestinal tract (GIT) antigen transport. Vaginal secretions of p.o.-immunized animals neutralize Chlamydia in vivo, resulting in significantly lower Chlamydia burden in the FRT and Chlamydia transport to the GIT. We also show that infection of the GIT is not necessary for induction of protective immunity in the FRT, a finding that is important for the development of p.o. subunit vaccines to target Chlamydia and possibly other sexually transmitted pathogens.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Chlamydiazzm321990; IgA; antibodies; female reproductive tract; mucosa; mucosal vaccines; neutralizing antibodies; vaccination; vaccine

Mesh:

Substances:

Year:  2020        PMID: 33139380      PMCID: PMC7927933          DOI: 10.1128/IAI.00413-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response.

Authors:  T Darville; C W Andrews; K K Laffoon; W Shymasani; L R Kishen; R G Rank
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

2.  Differences in outer membrane proteins of the lymphogranuloma venereum and trachoma biovars of Chlamydia trachomatis.

Authors:  B E Batteiger; W J Newhall; R B Jones
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

3.  Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility.

Authors:  L M de la Maza; S Pal; A Khamesipour; E M Peterson
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

4.  Humoral immune response in acquired immunity to chlamydial genital infection of female guinea pigs.

Authors:  R G Rank; A L Barron
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

5.  The Chromosome-Encoded Hypothetical Protein TC0668 Is an Upper Genital Tract Pathogenicity Factor of Chlamydia muridarum.

Authors:  Turner Allen Conrad; Siqi Gong; Zhangsheng Yang; Patrick Matulich; Jonathon Keck; Noah Beltrami; Chaoqun Chen; Zhou Zhou; Jin Dai; Guangming Zhong
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

6.  Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix.

Authors:  R C Brunham; C C Kuo; L Cles; K K Holmes
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

7.  Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection.

Authors:  K H Ramsey; L S Soderberg; R G Rank
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

8.  Humoral immune response to chlamydial genital infection of mice with the agent of mouse pneumonitis.

Authors:  K H Ramsey; W J Newhall; R G Rank
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

9.  Chlamydial infection of the gastrointestinal tract: a reservoir for persistent infection.

Authors:  Laxmi Yeruva; Nicole Spencer; Anne K Bowlin; Yin Wang; Roger G Rank
Journal:  Pathog Dis       Date:  2013-07-10       Impact factor: 3.166

10.  Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

Authors:  Connor P O'Meara; Charles W Armitage; Marina C G Harvie; Peter Timms; Nils Y Lycke; Kenneth W Beagley
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more
  2 in total

Review 1.  Immunopathogenesis of genital Chlamydia infection: insights from mouse models.

Authors:  Jacob Dockterman; Jörn Coers
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.951

2.  Enhanced IgA coating of bacteria in women with Lactobacillus crispatus-dominated vaginal microbiota.

Authors:  Annelot C Breedveld; Heleen J Schuster; Robin van Houdt; Rebecca C Painter; Reina E Mebius; Charlotte van der Veer; Sylvia M Bruisten; Paul H M Savelkoul; Marjolein van Egmond
Journal:  Microbiome       Date:  2022-01-24       Impact factor: 14.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.